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Strengths and limitations of this study
 ► We used a randomised controlled trial design and 
implemented the intervention in a real editorial 
context.
 ► Outcome assessment was blinded and in duplicate.
 ► We focused only on eight items of one reporting 
guideline (Consolidated Standards of Reporting 
Trials).
 ► The intervention was performed in only one journal.
AbStrACt
Objective To evaluate the impact of an editorial 
intervention to improve completeness of reporting of 
reports of randomised trials.
Design Randomised controlled trial (RCT).
Setting BMJ Open’s quality improvement programme.
Participants 24 manuscripts describing RCTs.
Interventions We used an R Shiny application to 
randomise manuscripts (1:1 allocation ratio, blocks of 
4) to the intervention (n=12) or control (n=12) group. 
The intervention was performed by a researcher with 
expertise in the content of the Consolidated Standards of 
Reporting Trials (CONSORT) and consisted of an evaluation 
of completeness of reporting of eight core CONSORT items 
using the submitted checklist to locate information, and 
the production of a report containing specific requests 
for authors based on the reporting issues found, provided 
alongside the peer review reports. The control group 
underwent the usual peer review.
Outcomes The primary outcome is the number of 
adequately reported items (0–8 scale) in the revised 
manuscript after the first round of peer review. The main 
analysis was intention- to- treat (n=24), and we imputed 
the scores of lost to follow- up manuscripts (rejected after 
peer review and not resubmitted). The secondary outcome 
is the proportion of manuscripts where each item was 
adequately reported. Two blinded reviewers assessed 
the outcomes independently and in duplicate and solved 
disagreements by consensus. We also recorded the 
amount of time to perform the intervention.
results Manuscripts in the intervention group (mean: 
7.01; SD: 1.47) were more completely reported than 
those in the control group (mean: 5.68; SD: 1.43) (mean 
difference 1.43, 95% CI 0.31 to 2.58). We observed the 
main differences in items 6a (outcomes), 9 (allocation 
concealment mechanism), 11a (blinding) and 17a 
(outcomes and estimation). The mean time to perform the 
intervention was 87 (SD 42) min.
Conclusions We demonstrated the benefit of involving 
a reporting guideline expert in the editorial process. 
Improving the completeness of RCTs is essential to 
enhance their usability.
trial registration number NCT03751878.
IntrODuCtIOn
The lack of transparency and accuracy of 
research reports has been pointed out as one 
of the main factors causing research waste.1 
Adequate reporting allows researchers to 
replicate results, generate new hypothesis 
or compare the results of different studies; 
allows healthcare professionals to make clin-
ical decisions; allows governments to change 
public policies; and helps patients to be aware 
of what healthcare options they have.2
Reporting guidelines (RGs) are sets of 
minimum recommendations for authors, 
usually in the form of a checklist, on how to 
report research methods and findings so that 
no relevant information is omitted.2 Since the 
inception in 1996 of the Consolidated Stan-
dards of Reporting Trials (CONSORT) for 
the reporting of randomised controlled trials 
(RCTs),3 hundreds of RGs for different study 
types, data, and preclinical and clinical areas 
have been developed.4 CONSORT is currently 
one of the most well- established RGs and has 
been revised and updated twice.5 6
Most RGs have not been evaluated as to 
whether they actually improve completeness 
of reporting. Even for those that have been 
shown to be beneficial, such as CONSORT, 
the degree of author adherence is poor.7 For 
this reason, a range of interventions aimed 
to improve adherence to RGs have been 
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box 1 Example of report reflecting the reporting issues 
found
Please make the following revisions:
 ► For CONSORT item 8a (‘Method used to generate the random al-
location sequence’), please report the exact method you used to 
generate the random allocation sequence.
 – Example from CONSORT: ‘Randomization sequence was creat-
ed using Stata M.N (StataCorp, College Station, TX) statistical 
software’.
 ► For CONSORT item 11a (‘If done, who was blinded after assignment 
to interventions and how’), please specify in ‘Trial design and set-
ting’ who was blinded in the study and do not just state that it was 
a double- blind randomised trial.
 – Example from CONSORT: ‘Whereas patients and physicians allo-
cated to the intervention group were aware of the allocated arm, 
outcome assessors and data analysts were kept blinded to the 
allocation’.
CONSORT, Consolidated Standards of Reporting Trials.
proposed, and the impact of some of these on complete-
ness of reporting has been evaluated. A recent scoping 
review identified and classified 31 interventions targeting 
different stakeholders, including authors, peer reviewers, 
journal editors, medical schools and ethics boards.8 
Among these, only four were assessed in RCTs and their 
effects were varied.9–12 Most of the studies included in 
the scoping review described observational studies that 
evaluated the pooled effect of different journal strategies, 
which ranged from making available editorial statements 
that endorse certain RGs, recommending or requiring 
authors to follow RGs in the ‘Instructions to authors’, 
and requiring authors to submit a completed RG check-
list together with the manuscript. However, these actions 
have been shown not to have the desired effect.13–16 In 
contrast, completeness of reporting improved remark-
ably when editors were in the process of checking adher-
ence to RGs.17
Recently, many biomedical journals have opted for 
requiring the submission of RG checklists alongside the 
manuscript. While sometimes checking these is dele-
gated to peer reviewers, journal editors generally report 
that this task goes beyond the role of these and that it 
may even decrease the quality of peer review reports.18 
If checking reporting issues becomes a standard exer-
cise for peer reviewers, some editors are afraid that peer 
reviewers may be less likely to comment on important 
aspects of a manuscript, such as its importance, novelty 
and relevance. Involving trained experts or administra-
tive staff could be a way to make the most of this editorial 
strategy.18
Study objectives
We describe an RCT to evaluate the effect of an editorial 
intervention performed by a researcher with expertise 
in CONSORT on the completeness of reporting of trials 
submitted to BMJ Open, compared with the standard peer 
review process.
MEthODS
trial design and study setting
This was a two- arm, parallel, randomised trial (1:1 allo-
cation ratio) conducted in collaboration with BMJ Open, 
an open- access general medical journal (published by 
the BMJ Publishing Group) that requests the submission 
of completed CONSORT checklists for RCTs. Prior to 
recruitment, we registered the study in  ClinicalTrials. gov 
and uploaded the study protocol.19
Eligibility criteria
Manuscripts were eligible for inclusion if (1) they were 
original research articles reporting the results of an RCT 
submitted to BMJ Open, (2) they had passed the first 
editorial filter and had been subsequently sent out for 
peer review, and (3) the authors of these manuscripts 
had provided a completed CONSORT checklist as part 
of the submission process. Apart from the standard, 
two- arm, parallel RCTs, which are covered by the stan-
dard CONSORT guidelines,20 we also included RCTs 
that require the use of the official CONSORT extensions 
for different design aspects (cluster,21 non- inferiority 
and equivalence,22 pragmatic,23 N- of-1 trials,24 pilot and 
feasibility,25 and within- person trials)26 and intervention 
types (herbal,27 non- pharmacological,28 acupuncture29 
and Chinese herbal medicine formulas30) in all areas of 
clinical research. We excluded studies that claimed to 
be RCTs but used deterministic allocation methods and 
secondary trial analysis studies.
Interventions
We designed a three- step intervention based on the results 
of our previous work,8 18 ensuring no disruption to usual 
editorial procedures. The lead investigator (DB), a PhD 
student with a background in statistics who had worked 
for 2 years on the topic of improving adherence to RGs 
and who had expertise in the content of CONSORT, 
performed the intervention. First, he assessed complete-
ness of reporting of eight core CONSORT items (see 
the following paragraph) using the submitted checklist 
to locate the information corresponding to each item. 
Second, he produced a standardised report containing 
precise requests to be addressed by authors. This report 
included a point by point description of the reporting 
issues found, requests to the authors to include the missing 
information (see example in box 1), as well as examples 
extracted from the CONSORT Explanation and Elabora-
tion (E&E) document.20 Finally, DB uploaded the report 
to the manuscript tracking system of the journal (Schol-
arOne) to make it accessible to the manuscript handling 
editor, who included this additional report in the deci-
sion letter to authors alongside the standard peer review 
reports. Manuscripts randomised to the control group 
underwent the usual peer review process. In figure 1, we 
display a schema of the study design.
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Figure 1 Schema of the study design. RCT, randomised 
controlled trial.
box 2 Core COnSOrt items considered
Five items in the methods section:
 ► Item 6a (‘Completely defined pre- specified primary and secondary 
outcome measures, including how and when they were assessed’).
 ► Item 8a (‘Method used to generate the random allocation sequence’).
 ► Item 9 (‘Mechanism used to implement the random allocation se-
quence (such as sequentially numbered containers), describing 
any steps taken to conceal the sequence until interventions were 
assigned’).
 ► Item 11a (‘If done, who was blinded after assignment to interven-
tions (for example, participants, care providers, those assessing 
outcomes) and how’).
 ► Item 11b (‘If relevant, description of the similarity of interventions’).
Three items in the results section:
 ► Item 13a (‘For each group, the numbers of participants who were 
randomly assigned, received intended treatment, and were anal-
ysed for the primary outcome’).
 ► Item 13b (‘For each group, losses and exclusions after randomisa-
tion, together with reasons’).
 ► Item 17a (‘For each primary and secondary outcome, results for 
each group, and the estimated effect size and its precision (such as 
95% confidence interval)’).
CONSORT, Consolidated Standards of Reporting Trials.
The intervention was focused on eight core CONSORT 
items (see box 2) which are essential for researchers eval-
uating the risk of bias of RCTs when conducting system-
atic reviews31 and which are usually poorly reported.32
We considered an item as adequately reported if all 
subparts of it were adequately reported, according to the 
CONSORT E&E document20 and the corresponding E&E 
documents for the extensions considered. For example, 
for CONSORT item 6a (‘Completely defined pre- specified 
primary and secondary outcome measures, including how 
and when they were assessed’), we required the following 
subparts to be adequately reported: (1) identified and 
completely defined primary and secondary outcomes, 
(2) analysis metric and methods of aggregation for each 
outcome, and (3) time points for each outcome.
The items corresponding to CONSORT extensions 
were assessed in addition to the standard CONSORT 
items. For example, we expected authors of a cluster 
randomised trial evaluating a pharmacological treatment 
to be using the standard CONSORT checklist for all eight 
items and the cluster extension for items 6a, 9, 13a, 13b 
and 17a. In contrast, the items requested by the pilot and 
feasibility extension substituted the standard CONSORT 
items, as specified in its E&E document.25 Once the 
recruitment had begun, we decided to discard the exten-
sion for non- pharmacological interventions as it was not 
being requested by the editors nor sent by the authors.
In online supplementary file 1, we present further 
details on the rules we used to deal with not applicable 
items and with certain aspects of specific items.
Outcomes
 ► Primary outcome: the mean score for completeness of 
reporting, defined as the mean number of adequately 
reported items in the first revised manuscript (0–8 
scale).
 ► Secondary outcome: proportion of manuscripts where 
each item was adequately reported.
In the design phase of the study, we considered two 
potential scenarios where included manuscripts could 
potentially be lost to follow- up: (1) when editors rejected 
a manuscript after peer review and (2) when authors 
did not return the revised manuscript within the period 
requested by the handling editor after a ‘Minor revi-
sion’ or ‘Major revision’ editorial decision (14 and 28 
days, respectively, plus, if necessary, the extra time that 
the editor considered appropriate). In the ‘Statistical 
methods’ section, we report the methods used to impute 
the study outcomes for lost to follow- up articles.
Outcome evaluation was performed independently 
and in duplicate by two senior researchers (EC, JJK) 
who were blinded to manuscript allocation and had 
experience as authors and reviewers of RCTs. They also 
assessed outcomes at baseline. In cases where a manu-
script was rejected after the first round of peer review, 
assessors could only evaluate it at baseline. However, they 
were not aware of the fate of that manuscript until after 
they had completed that evaluation. More details about 
the outcome assessment process can be found in online 
supplementary file 2.
For each of the manuscripts in the intervention group, 
we also recorded the amount of time it took the lead 
investigator to perform the intervention.
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harms
We analysed whether our intervention caused the 
following unintended effects: higher proportion of 
manuscript rejections after the first round of peer review 
and delays in the submission of the revised manuscripts 
by authors.
Pilot work
To inform the sample size calculation, the lead investi-
gator assessed 12 randomly selected RCTs published in 
BMJ Open between April 2018 and September 2018. The 
proportions of adequately reported items observed in 
these manuscripts were used to estimate the scores for 
completeness of reporting of the manuscripts in the 
control group (usual peer review).
Furthermore, outcome assessors (EC, JJK) practised 
the evaluation of completeness of reporting by assessing 
6 of the 12 RCTs that were mentioned.
Power analysis
According to the assessment described in the ‘Pilot work’ 
section, the estimated probabilities that manuscripts in 
the control group adequately reported 0, 1, 2,…, and 8 
items were 0, 0, 0, 0, 0, 0.17, 0.33, 0.33 and 0.17, respec-
tively. With the intervention, we aimed to bring this distri-
bution to 0, 0, 0, 0, 0, 0, 0, 0.5 and 0.5. In other words, 
manuscripts in the intervention group were expected to 
be adequately reporting seven or eight items 50% of the 
time, respectively.
In order to relax the strong required assumptions 
behind using a t- test for a reduced sample size, we used 
bootstrapping, a simple yet powerful non- parametric 
technique.33 First, given the probability distributions 
mentioned, we performed 10 000 simulations of the 
scores of n manuscripts. We resampled each of these 
simulations 10 000 times in order to calculate the 95% CI 
of the mean difference between groups. Finally, we calcu-
lated the study power by counting for how many of the 10 
000 simulations the lower limit of this 95% CI was over 0.
Choosing a sample size of 24 manuscripts (12 per arm) 
and following the procedure above gave us 90% power 
(alpha=0.05, two- tailed). The R code used can be found 
in online supplementary file 3, script A.
randomisation and blinding
Prior to recruitment of manuscripts, DB screened auto-
mated reports listing original research submissions to 
BMJ Open on ScholarOne, daily, including their identifica-
tion (ID), date of submission, title, abstract and different 
parameters related to their peer review status. RCTs were 
identified for possible inclusion based on the title and 
abstract and then checked against our eligibility criteria 
until the desired sample size was achieved.
Every time a manuscript met our eligibility criteria, DB 
introduced its ID into an R Shiny application34 created 
by a senior statistician (JAG) (see online supplementary 
file 3, script B), which randomised the manuscript to the 
intervention or the control group (1:1 allocation ratio, 
blocks of 4). Manuscripts were stratified according to 
whether there was an applicable CONSORT extension for 
that study or not. To avoid allocation bias, each ID could 
only be introduced once.
As part of the usual submission process, all authors are 
informed that the BMJ Publishing Group has a quality 
improvement programme and their manuscript might be 
entered into a study. However, authors of included manu-
scripts were not explicitly informed that their manuscripts 
were part of an RCT.
Outcome assessors were blinded to allocation and to 
each other’s evaluation. Handling editors of the included 
manuscripts and the investigator performing the inter-
vention (DB) were not blinded.
Statistical methods
We carried out statistical analysis using R V.3.6.0.35
For the primary outcome, we adjusted a linear regres-
sion model with the baseline score of the manuscript as 
the only covariate. We calculated the 95% CI using boot-
strapping (see online supplementary file 3, script C).
The main analysis of the primary outcome was 
intention- to- treat: all manuscripts were included in this 
analysis regardless of whether they were lost to follow- up. 
We imputed the scores of lost to follow- up manuscripts 
with a value of 8- b, where b was the baseline score of the 
manuscript. This imputation strategy aimed to reflect the 
fact that rejecting RCTs of low baseline quality could be 
considered an editorial success. In addition, we assessed 
the sensitivity of the results by carrying out a complete 
case analysis and analysing the best case (manuscripts in 
the intervention group reached the maximum score and 
controls did not improve) and worst case (manuscripts 
in the intervention group did not improve and controls 
reached the maximum score) scenarios.
We did not plan any subgroup analysis (see protocol19) 
and so none is reported.
Deviations from the protocol
The last criterion (3: authors of the manuscripts had 
provided a completed CONSORT checklist) was not 
included in the first version of the protocol, but we 
implemented it before recruitment started. The reason 
was that, despite the submission of the CONSORT check-
list for trials being mandatory, we observed that handling 
editors were occasionally overlooking this requirement 
and sending out manuscripts of trials for peer review 
that did not include one. Second, we initially used a t- test 
to calculate the study power and planned to use it for 
the primary outcome analysis. However, for the reasons 
described in the ‘Power analysis’ section, we used a boot-
strap approach and the study power increased from the 
85% stated in the protocol to 90%. Third, we decided to 
assess the baseline scores for completeness of reporting 
for the included manuscripts in order to adjust for these 
in the primary outcome analysis. With this we tried to 
avoid that a difference in the baseline scores between the 
two groups could make the intervention seem to have a 
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Figure 2 CONSORT flow diagram. CONSORT, Consolidated 
Standards of Reporting Trials; RCT, randomised controlled 
trial.







  Standard parallel- group 7 (58%) 7 (58%)
  Cluster 2 (17%) 1 (8%)
  Pilot and feasibility 3 (25%) 4 (33%)
Type of intervention
  Pharmacological 2 (17%) 4 (33%)
  Non- pharmacological 10 (83%) 8 (67%)
  Behavioural 4 (33%) 3 (25%)
  E- health and tele- health 
strategies
3 (25%) 2 (17%)
  Medical devices 2 (17%) 1 (8%)
  Surgery 0 (0%) 1 (8%)
  Others 1 (8%) 1 (8%)
Single- centre or multicentre
  Single- centre 8 (67%) 5 (42%)
  Multicentre 4 (33%) 7 (58%)
Number of participants
  ≤50 5 (42%) 2 (17%)
  >50 and ≤100 3 (25%) 7 (58%)
  >100 4 (33%) 3 (25%)
Registered in a trial registry
  Yes 11 (92%) 11 (92%)
  No 1 (8%) 1 (8%)
First author’s affiliation
  Asia 3 (25%) 3 (25%)
  UK 3 (25%) 5 (42%)
  Europe 2 (17%) 3 (25%)
  USA 2 (17%) 0 (0%)
  Australia 2 (17%) 0 (0%)
  Brazil 0 (0%) 1 (8%)
Sponsorship
  Investigator- initiated 12 (100%) 10 (83%)
  Industry- initiated 0 (0%) 2 (17%)
larger or smaller effect than it actually had. Finally, we 
added a best- case and worst- case scenario analysis to assess 
the sensitivity of the primary outcome results.
reporting guidelines
We report this manuscript in accordance with CONSORT 
2010.6
Patient and public involvement
Patients were not study participants and were not involved 
in setting the research question, designing the study, in 
the conduct of the study or in the interpretation of the 
results.
rESultS
Between 31 October 2018 and 4 April 2019, we screened 
62 manuscripts that described RCTs submitted to BMJ 
Open. Among these, we excluded 38 either because they 
were rejected without peer review (n=34) or because the 
authors did not provide the CONSORT checklist (n=4). 
We randomised the remaining 24 to the intervention 
(n=12) or control (n=12) groups. Six (25%) manuscripts 
were lost to follow- up (intervention n=3, control n=3) as 
they were rejected after the first round of peer review and 
therefore not returned to authors for revision (scenario 
1 in the Outcomes section). No manuscripts were lost to 
follow- up in scenario 2 as all authors returned the revised 
manuscripts within the given time. Therefore, 18 manu-
scripts (intervention n=9, control n=9) were revised by 
authors. Figure 2 shows the flow diagram of the study.
Most manuscripts (n=19, 79%) required at least one 
extension: non- pharmacological (intervention n=10, 
control n=8), pilot and feasibility (n=3, n=4), and cluster 
(n=2, n=1). Table 1 displays the baseline characteristics of 
the included manuscripts.
The mean (SD) baseline score for completeness of 
reporting (0–8 scale) prior to peer review in the inter-
vention (n=12) and control (n=12) groups was 4.35 
(1.88) and 4.85 (1.79), respectively. The mean (SD) base-
line score of the manuscripts that later passed the first 
round of peer review (n=18) was much more complete 
(scores almost double) than those that were rejected 
after the first round of peer review (n=6): 5.23 (1.35) vs 
2.68 (1.75).
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Mean (SD) Mean difference in 
final scores* (95% CI)Baseline Final Baseline Final
Completeness of reporting (0–8 scale) with 
imputation (n=24)
4.35 (1.88) 7.01 (1.47) 4.85 (1.79) 5.68 (1.43) 1.43 (0.31 to 2.58)
Completeness of reporting (0–8 scale) without 
imputation (complete case analysis, n=18)
5.01 (1.32) 7.45 (1.00) 5.46 (1.41) 5.90 (1.35) 1.75 (0.80 to 2.75)
Completeness of reporting (0–8 scale) in the 
best- case scenario (n=24)
4.35 (1.88) 7.59 (0.89) 4.85 (1.79) 5.18 (1.89) 2.62 (1.49 to 3.65)
Completeness of reporting (0–8 scale) in the 
worst- case scenario (n=24)
6.18 (2.61) 6.43 (1.49) 0.03 (−1.45 to 1.63)
*Adjusted for baseline score.
Figure 3 Evolution of the scores for all manuscripts that passed the first round of peer review (n=18).
Primary outcome
For the intention- to- treat analysis (n=24), the manuscripts 
that received the intervention were more completely 
reported than the ones that underwent the standard 
review process (intervention group: mean 7.01 (SD 1.47) 
vs control group: mean 5.68 (SD 1.43)). After adjusting 
for the baseline score, the mean difference in scores 
between the two groups was 1.43 (95% CI 0.31 to 2.58); 
the manuscripts in the intervention group reported on 
average 1.43 (out of 8) items more adequately than those 
receiving the standard peer review. Regarding the sensi-
tivity analysis, for the complete case (n=18) the mean 
(SD) scores for the intervention and control groups 
were 7.45 (1.00) and 5.90 (1.35), giving an adjusted 
difference of 1.75 (95% CI 0.80 to 2.75). The best- case 
and worst- case scenario analysis (n=24) led to adjusted 
differences of 2.62 (95% CI 1.49 to 3.65) and 0.03 (95% 
CI −1.45 to 1.63), respectively. Table 2 summarises these 
results.
Figure 3 shows the evolution of the 18 manuscripts that 
were revised and resubmitted. From the nine manuscripts 
in the intervention group, six of them achieved the 
maximum score and another two improved. In contrast, 
the only manuscript in the control group that reached 
the maximum score already had that score at baseline. 
Three manuscripts in the control group slightly improved 
(1, 1 and 2 points, respectively). We identified that three 
out of four of these improvements were the result of 
comments made by the standard peer reviewers, rather 
than the authors themselves.
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Figure 4 Proportion of manuscripts (n=18) where each CONSORT item is adequately reported. CONSORT items: 6a: 
‘Completely defined pre- specified primary and secondary outcome measures, including how and when they were assessed’; 
8a: ‘Method used to generate the random allocation sequence’; 9: ‘Mechanism used to implement the random allocation 
sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions 
were assigned’; 11a: ‘If done, who was blinded after assignment to interventions (for example, participants, care providers, 
those assessing outcomes) and how’); 11b: ‘If relevant, description of the similarity of interventions’; 13a: ‘For each group, 
the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary 
outcome’; 13b: ‘For each group, losses and exclusions after randomisation, together with reasons’; 17a: ‘For each primary and 
secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)’). 
CONSORT, Consolidated Standards of Reporting Trials; Cont, control group; Int, intervention group.
Secondary outcome
Figure 4 displays the proportions of manuscripts where 
each CONSORT item was adequately reported. We 
observed the main differences favouring the intervention 
group in items 6a (outcomes), 9 (allocation concealment 
mechanism), 11a (blinding) and 17a (outcomes and 
estimation).
Feasibility of the intervention
The mean (SD) time taken to perform the intervention 
was 87 (42) min. Online supplementary file 4 displays a 
scatter plot that compares the amount of time spent to 
perform the intervention and the baseline score of the 
12 manuscripts in the intervention group. There was no 
correlation between these two variables (r=0.08).
harms
We did not identify any unintended effects. There were 
no differences between the intervention and the control 
groups for the proportion of manuscripts that were 
rejected after the first round of peer review (3 of 12, 25%, 
for each group). Furthermore, all authors submitted the 
revised manuscripts within the period requested by the 
handling editor.
DISCuSSIOn
We found that the introduction during the peer review 
process of an editorial intervention performed by a 
researcher with expertise in the content of CONSORT 
significantly improved the completeness of reporting of 
trials submitted to BMJ Open compared with standard 
peer review. Six of the nine manuscripts in the interven-
tion group achieved the maximum score and another two 
improved. In contrast, the only manuscript in the control 
group with the maximum score at follow- up already had 
reached that score at baseline. We observed the main 
differences favouring the intervention group in items 6a 
(outcomes), 9 (allocation concealment mechanism), 11a 
(blinding) and 17a (outcomes and estimation). More-
over, providing authors with extra comments on reporting 
issues did not seem to discourage them from revising the 
manuscript as all authors returned the revised manu-
scripts within the standard 28 days requirement.
Strengths and limitations
This study has several strengths: the randomised trial 
design; the fact that the intervention was performed in a 
real editorial context alongside peer review reports with 
no disruption to usual editorial procedures; and the fact 
that the outcome assessment process was blinded and in 
duplicate.
We also note some limitations that affect the generalis-
ability of our results. Our intervention was focused only 
on CONSORT, which is one of the most well- established 
RGs. It could potentially be more difficult for authors 
to fully address reviewers’ comments about other less 
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familiar RGs. We only included one journal and the same 
effect might not be observed in other journals. None-
theless, we purposefully selected a very large general 
medical journal receiving international submissions 
across multiple specialties. We considered only eight core 
CONSORT items that are essential for evaluating the risk 
of bias of RCTs and not the whole checklist.
Implications
Given the importance of improving the completeness of 
reporting of randomised trials and given the ineffective-
ness of the strategies that biomedical journals are currently 
implementing,13–16 it is time to take a step forward. Our 
study provides empirical evidence of the effectiveness of 
involving in the peer review process a researcher with 
expertise in CONSORT. In this study, the intervention 
was carried out by a PhD student and was implemented 
alongside peer review. However, this intervention could 
potentially be done by trained editorial staff, editors or 
external consultants. The demonstrated benefits of our 
intervention should encourage journal editors to find the 
best way to make this feasible.
We note that the complete case analysis and the best- 
case scenario of the sensitivity analysis point to a larger 
effect of the intervention than the main analysis. The 
worst- case scenario shows no effect. However, this scenario 
would assume (1) that the three rejected manuscripts in 
the intervention group would not improve from baseline; 
and (2) that all manuscripts in the control group would 
reach the maximum score. This scenario seems highly 
unlikely given that eight out of nine manuscripts that 
were not rejected in the intervention group improved 
from baseline and that only three controls improved and 
none of these reached the maximum score.
More than two decades ago, scientists started to discuss 
the importance of including statistical reviews as part of 
the publication process.36 Nowadays, statistical reviews 
have become widespread among top medical journals. 
These are usually performed by a statistician and focus 
on the methodological and statistical aspects of the study. 
As methodological issues are often not fixable, statistical 
reviews are key to determining the fate of manuscripts 
and preventing unsound research getting published.37 
Completeness of reporting reviews should also become 
a key component in the publication system. As reporting 
issues are often improvable, these reviews should not 
generally aim to determine whether a manuscript should 
be published or not, but to improve their transparency. 
This would both help editors and peer reviewers make 
decisions on the manuscripts and improve the usability of 
published papers.
A few other RCTs have assessed different strategies 
for improving adherence to RGs. A recent RCT did 
not show that requesting authors to submit a checklist 
improves completeness of reporting and called for more 
stringent editorial policies.16 The implementation of a 
writing aid tool for authors (CONSORT- based WEB tool) 
led to a moderate improvement in the completeness of 
reporting,11 whereas getting a statistician to perform an 
additional review against RGs showed a slightly positive 
but smaller than hypothesised effect.10 Suggesting peer 
reviewers to check RGs9 and implementing the web- 
based tool WebCONSORT at the manuscript revision 
stage showed no positive impact.12 However, comparisons 
between the results of our study and these RCTs must be 
made with caution as they targeted different RGs and 
were carried out in different settings.
The time taken for us to perform the intervention 
(87 min on average, with great variation between manu-
scripts) is clearly a barrier to wider implementation. 
Future research could evaluate whether this inter-
vention should be focused on the whole CONSORT 
checklist, which would make this strategy even more time- 
consuming, or only on a few core items (such as those 
we found to be poorly reported). Also, it would be inter-
esting to assess whether similar benefits can be obtained 
for other widely used RGs, such as the Standard Protocol 
Items: Recommendations for Interventional Trials38 or 
the Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses.39 Furthermore, this intervention could 
also be tested at other points in the editorial process, for 
example before the first decision is made on the manu-
script or between the first decision and the invitation of 
external peer reviewers. For this study, we discarded both 
options for pragmatic reasons, as we did not want to alter 
the usual editorial process. While the first could be too 
resource- intensive for journals, the latter would imply 
the same effort and the manuscript would undergo more 
transparent and accurate peer review, which could make 
the task of peer reviewers and handling editors easier 
and more efficient. We strongly recommend that journals 
always carry out experiments in real editorial contexts, 
such as this study, before considering making any changes 
in their policies.
COnCluSIOnS
This study provides evidence that involving a researcher 
with expertise in CONSORT in the process of evaluating 
RG checklists submitted by authors significantly improves 
the completeness of reporting of randomised trials. This 
is essential to reducing the research waste associated 
within adequate reporting of RCT methods and findings. 
Journal editors should consider revising their peer review 
processes to find ways to make this intervention workable, 
tailoring it to their preferences.
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